ALXO Share Price | ALX Oncology Holdings, Inc. Stock Analysis & Recommendation

Q: What does ALX Oncology Holdings, Inc. do?

Overview:ALX Oncology Holdings, Inc. is a clinical-stage immuno-oncology company focused on developing therapies that block the CD47 checkpoint pathway to enable patients to fight cancer, operating in the Miscellaneous industry with a micro-cap market capitalization.Financial Snapshot:Most recent Net Profit: -31 Million (Quarterly Results - Mar 2025) Market-cap: USD 26.47 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.97 Return on Equity: -147.26% Price to Book: 0.30 Contact Details:Address: 866 Malcolm Road, Suite 100, BURLINGAME CA: 94010 Tel: 1 650 4667125 Fax: 1 302 6555049 Website: http://alxoncology.com/

Q: Is ALX Oncology Holdings, Inc. overvalued or undervalued?

As of 17 May 2021, the valuation grade for ALX Oncology Holdings, Inc. moved from risky to does not qualify. The company is currently considered overvalued given its significant operational losses and negative return metrics. Key ratios include a price to book value of 0.35, an EV to EBIT of 0.40, and a ROE of -147.26%. In comparison to peers, Universal Technical Institute, Inc. has a fair valuation with a P/E ratio of 31.55, while Emerald Holding, Inc. is deemed expensive with a P/E of 41.37. The stark contrast in valuations highlights ALX's struggles, particularly as it has underperformed significantly against the S&P 500, with a year-to-date return of -72.47% compared to the index's 2.44%. Overall, ALX Oncology Holdings appears to be overvalued in its current state.

Q: Is ALX Oncology Holdings, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for ALX Oncology Holdings, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. While the weekly MACD and OBV are mildly bullish, the overall sentiment is tempered by the monthly Bollinger Bands showing bearishness and the KST indicating a bearish trend. The stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -34.73% versus the S&P 500's 12.22%, and a one-year return of -49.07% compared to 17.14% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

517.83 k

Shareholding (Sep 2025)

FII

4.69%

Held by 54 FIIs

DII

45.4%

Held by 24 DIIs

Promoter

30.75%

How big is ALX Oncology Holdings, Inc.?

22-Jun-2025

As of Jun 18, ALX Oncology Holdings, Inc. has a market capitalization of 26.47 million, with net sales of 0.00 million and a net profit of -130.02 million. The balance sheet shows shareholder's funds of 113.62 million and total assets of 147.78 million.

View full answer

What does ALX Oncology Holdings, Inc. do?

22-Jun-2025

ALX Oncology Holdings, Inc. is a clinical-stage immuno-oncology company developing therapies targeting the CD47 checkpoint pathway to combat cancer. It has a market capitalization of $26.47 million and reported a net profit loss of $31 million as of March 2025.

View full answer

Who are in the management team of ALX Oncology Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of ALX Oncology Holdings, Inc. includes Dr. Corey Goodman as Executive Chairman and Dr. Jaume Pons as President and CEO. The Board of Directors also features independent members Ms. Rekha Hemrajani, Mr. Jason Lettmann, Mr. Jack Nielsen, and Dr. Graham Walmsley.

View full answer

Is ALX Oncology Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of May 17, 2021, ALX Oncology Holdings, Inc. is considered overvalued due to significant operational losses and negative return metrics, with a valuation grade that has shifted from risky to does not qualify, underperforming the S&P 500 with a year-to-date return of -72.47%.

View full answer

Is ALX Oncology Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, ALX Oncology Holdings, Inc. is in a mildly bearish trend, influenced by daily moving averages, despite some bullish indicators, and has significantly underperformed the S&P 500 with a year-to-date return of -34.73%.

View full answer

Compare ALX Oncology Holdings, Inc. with Similar Stocks

P3 Health Partners, Inc.InfuSystem Holdings, Inc.Information Services Group, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 80 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.08

Return on Equity

-234.01%

Price to Book

1.78

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-22 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

130.53%

6 Months

30.38%

1 Year

-76.24%

2 Years

-74.25%

3 Years

-69.64%

4 Years

-96.62%

5 Years

0.0%

ALX Oncology Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-223.26%

EBIT to Interest (avg)

-92.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.97

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

92.35%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.35

EV to EBIT

0.40

EV to EBITDA

0.41

EV to Capital Employed

-22.96

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-147.26%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Sideways

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 33 Schemes (19.16%)

Foreign Institutions

Held by 54 Foreign Institutions (4.69%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 28.01% vs 39.80% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.40",
          "val2": "-32.30",
          "chgp": "30.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-22.10",
          "val2": "-30.70",
          "chgp": "28.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.17% vs -30.20% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.60",
          "val2": "-169.40",
          "chgp": "16.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "1.60",
          "chgp": "6.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-134.80",
          "val2": "-160.80",
          "chgp": "16.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-22.40

-32.30

30.65%

Interest

0.40

Exceptional Items

0.00

Consolidate Net Profit

-22.10

-30.70

28.01%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 28.01% vs 39.80% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-141.60

-169.40

16.41%

Interest

1.70

1.60

6.25%

Exceptional Items

0.00

Consolidate Net Profit

-134.80

-160.80

16.17%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 16.17% vs -30.20% in Dec 2023

All Annual Results

Company CV

About ALX Oncology Holdings, Inc.

ALX Oncology Holdings, Inc.

Miscellaneous

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.

Company Coordinates

Company Details

866 Malcolm Road, Suite 100 , BURLINGAME CA : 94010

Tel: 1 650 4667125

http://alxoncology.com/

Registrar Details

ALX Oncology Holdings, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is ALX Oncology Holdings, Inc.?

Watch in Real-Time

What does ALX Oncology Holdings, Inc. do?

Who are in the management team of ALX Oncology Holdings, Inc.?

Is ALX Oncology Holdings, Inc. overvalued or undervalued?

Is ALX Oncology Holdings, Inc. technically bullish or bearish?

Compare ALX Oncology Holdings, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About ALX Oncology Holdings, Inc.

Company Coordinates